JP2008541730A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008541730A5 JP2008541730A5 JP2008513739A JP2008513739A JP2008541730A5 JP 2008541730 A5 JP2008541730 A5 JP 2008541730A5 JP 2008513739 A JP2008513739 A JP 2008513739A JP 2008513739 A JP2008513739 A JP 2008513739A JP 2008541730 A5 JP2008541730 A5 JP 2008541730A5
- Authority
- JP
- Japan
- Prior art keywords
- adenoviral
- influenza
- recombinant
- gene
- plasmid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000013612 plasmid Substances 0.000 claims 36
- 241000701161 unidentified adenovirus Species 0.000 claims 32
- 206010022000 influenza Diseases 0.000 claims 25
- 108090000623 proteins and genes Proteins 0.000 claims 22
- 239000013598 vector Substances 0.000 claims 19
- 238000000034 method Methods 0.000 claims 17
- 210000004027 cell Anatomy 0.000 claims 12
- 108020004707 nucleic acids Proteins 0.000 claims 11
- 150000007523 nucleic acids Chemical class 0.000 claims 11
- 102000039446 nucleic acids Human genes 0.000 claims 11
- 108700026220 vif Genes Proteins 0.000 claims 10
- 210000001236 prokaryotic cell Anatomy 0.000 claims 9
- 230000003115 biocidal effect Effects 0.000 claims 8
- 230000010076 replication Effects 0.000 claims 8
- 241000588724 Escherichia coli Species 0.000 claims 6
- 238000004519 manufacturing process Methods 0.000 claims 6
- 238000004806 packaging method and process Methods 0.000 claims 5
- 101710154606 Hemagglutinin Proteins 0.000 claims 3
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 claims 3
- 108010006232 Neuraminidase Proteins 0.000 claims 3
- 108010061100 Nucleoproteins Proteins 0.000 claims 3
- 101710093908 Outer capsid protein VP4 Proteins 0.000 claims 3
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 claims 3
- 101710176177 Protein A56 Proteins 0.000 claims 3
- 230000001580 bacterial effect Effects 0.000 claims 3
- 239000012634 fragment Substances 0.000 claims 3
- 230000006801 homologous recombination Effects 0.000 claims 3
- 238000002744 homologous recombination Methods 0.000 claims 3
- 208000037797 influenza A Diseases 0.000 claims 3
- 208000037798 influenza B Diseases 0.000 claims 3
- 208000037799 influenza C Diseases 0.000 claims 3
- 239000011159 matrix material Substances 0.000 claims 3
- 238000002360 preparation method Methods 0.000 claims 3
- 230000035897 transcription Effects 0.000 claims 3
- 238000013518 transcription Methods 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 241000701022 Cytomegalovirus Species 0.000 claims 2
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 claims 2
- 239000004098 Tetracycline Substances 0.000 claims 2
- 108010084455 Zeocin Proteins 0.000 claims 2
- 229960000723 ampicillin Drugs 0.000 claims 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 claims 2
- 239000003242 anti bacterial agent Substances 0.000 claims 2
- 229960005091 chloramphenicol Drugs 0.000 claims 2
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 claims 2
- 229930027917 kanamycin Natural products 0.000 claims 2
- 229960000318 kanamycin Drugs 0.000 claims 2
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 claims 2
- 229930182823 kanamycin A Natural products 0.000 claims 2
- CWCMIVBLVUHDHK-ZSNHEYEWSA-N phleomycin D1 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC[C@@H](N=1)C=1SC=C(N=1)C(=O)NCCCCNC(N)=N)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C CWCMIVBLVUHDHK-ZSNHEYEWSA-N 0.000 claims 2
- 230000008488 polyadenylation Effects 0.000 claims 2
- 108091008146 restriction endonucleases Proteins 0.000 claims 2
- 229960002180 tetracycline Drugs 0.000 claims 2
- 229930101283 tetracycline Natural products 0.000 claims 2
- 235000019364 tetracycline Nutrition 0.000 claims 2
- 150000003522 tetracyclines Chemical class 0.000 claims 2
- 102000007469 Actins Human genes 0.000 claims 1
- 108010085238 Actins Proteins 0.000 claims 1
- 108010088751 Albumins Proteins 0.000 claims 1
- 102000009027 Albumins Human genes 0.000 claims 1
- 241000894006 Bacteria Species 0.000 claims 1
- 241001465754 Metazoa Species 0.000 claims 1
- 102000010292 Peptide Elongation Factor 1 Human genes 0.000 claims 1
- 108010077524 Peptide Elongation Factor 1 Proteins 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 210000005260 human cell Anatomy 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 230000002163 immunogen Effects 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US68363805P | 2005-05-23 | 2005-05-23 | |
| PCT/US2006/020350 WO2006127956A2 (en) | 2005-05-23 | 2006-05-23 | Rapid production of adenovirus-free recombinant adenovirus vectors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008541730A JP2008541730A (ja) | 2008-11-27 |
| JP2008541730A5 true JP2008541730A5 (https=) | 2009-07-09 |
Family
ID=37452858
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008513739A Pending JP2008541730A (ja) | 2005-05-23 | 2006-05-23 | 高力価かつ複製コンピテントアデノウイルス不含である組換えアデノウイルスベクターの迅速な作成法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20090175897A1 (https=) |
| EP (1) | EP1899470A4 (https=) |
| JP (1) | JP2008541730A (https=) |
| KR (1) | KR20080052512A (https=) |
| CN (1) | CN101248186A (https=) |
| AU (1) | AU2006249877A1 (https=) |
| CA (1) | CA2609276A1 (https=) |
| WO (1) | WO2006127956A2 (https=) |
| ZA (1) | ZA200710860B (https=) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040009936A1 (en) | 1999-05-03 | 2004-01-15 | Tang De-Chu C. | Vaccine and drug delivery by topical application of vectors and vector extracts |
| JP2009512421A (ja) * | 2005-08-15 | 2009-03-26 | ヴァクシン インコーポレイテッド | 非複製性ベクターワクチン投与による鳥類への免疫方法 |
| CN102203242B (zh) | 2008-11-03 | 2013-06-12 | 克鲁塞尔荷兰公司 | 产生腺病毒载体的方法 |
| WO2010085984A1 (en) * | 2009-02-02 | 2010-08-05 | Okairos Ag | Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof |
| CN102549152B (zh) * | 2009-07-31 | 2015-11-25 | 帕克斯瓦克斯股份有限公司 | 基于腺病毒的载体 |
| WO2012011955A2 (en) * | 2010-07-21 | 2012-01-26 | Duke University | Compositions and methods for production and screening of monoclonal antibodies |
| KR102104650B1 (ko) | 2011-03-21 | 2020-04-24 | 알티뮨 인크. | 급속 및 지속적 면역학적제제-치료제 |
| US10183069B2 (en) | 2011-03-21 | 2019-01-22 | Altimmune Inc. | Rapid and prolonged immunologic-therapeutic |
| KR101557974B1 (ko) * | 2013-03-29 | 2015-10-08 | 주식회사 에스씨티 | 혈청형６ 재조합 아데노바이러스 제조용 벡터 |
| AU2014315124A1 (en) * | 2013-09-06 | 2016-04-07 | Altimmune Inc. | Methods and compositions for viral vectored vaccines |
| AU2015311704B2 (en) | 2014-09-07 | 2021-12-09 | Selecta Biosciences, Inc. | Methods and compositions for attenuating gene editing anti-viral transfer vector immune responses |
| US9616114B1 (en) | 2014-09-18 | 2017-04-11 | David Gordon Bermudes | Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity |
| US10676723B2 (en) | 2015-05-11 | 2020-06-09 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| WO2017074517A1 (en) * | 2015-10-30 | 2017-05-04 | Seracare Life Sciences, Inc. | Adenovirus control virus |
| CN106853247A (zh) * | 2015-12-08 | 2017-06-16 | 中国农业科学院兰州兽医研究所 | 一种制备狂犬病活载体疫苗的方法及其产品和用途 |
| US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| US11180535B1 (en) | 2016-12-07 | 2021-11-23 | David Gordon Bermudes | Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria |
| US20180193482A1 (en) | 2017-01-07 | 2018-07-12 | Selecta Biosciences, Inc. | Patterned dosing of immunosuppressants coupled to synthetic nanocarriers |
| MX2019011599A (es) | 2017-03-30 | 2019-12-19 | Univ Queensland | Moleculas quimericas y usos de las mismas. |
| CN110892064A (zh) * | 2017-07-25 | 2020-03-17 | 牛津遗传学有限公司 | 腺病毒载体 |
| WO2019040994A1 (en) | 2017-09-01 | 2019-03-07 | The Australian National University | IMMUNOREGULATOR MOLECULES AND USES THEREOF |
| AU2018347583A1 (en) | 2017-10-13 | 2020-05-21 | Selecta Biosciences, Inc. | Methods and compositions for attenuating anti-viral transfer vector IgM responses |
| JP2021515037A (ja) | 2018-02-26 | 2021-06-17 | アントルクス，インコーポレーテッド | 寛容原性リポソーム及びその使用方法 |
| JP2022526632A (ja) * | 2019-04-06 | 2022-05-25 | アルティミューン インコーポレーティッド | 広範囲及び持続性のインフルエンザワクチン |
| CN114126666A (zh) | 2019-04-28 | 2022-03-01 | 西莱克塔生物科技公司 | 用于治疗针对病毒转移载体具有预先存在的免疫力的对象的方法 |
| CA3141863A1 (en) | 2019-05-28 | 2020-12-03 | Selecta Biosciences, Inc. | Methods and compositions for attenuated anti-viral transfer vector immune response |
| WO2023064367A1 (en) | 2021-10-12 | 2023-04-20 | Selecta Biosciences, Inc. | Methods and compositions for attenuating anti-viral transfer vector igm responses |
| WO2023172624A1 (en) | 2022-03-09 | 2023-09-14 | Selecta Biosciences, Inc. | Immunosuppressants in combination with anti-igm agents and related dosing |
| CN116179604B (zh) * | 2022-08-31 | 2025-08-26 | 上海锦斯生物技术有限公司 | 一种降低回复突变频率的重组5型腺病毒载体及其构建方法 |
| CN119432919B (zh) * | 2024-11-12 | 2025-07-01 | 北京因美未来生物医药科技有限公司 | 减少复制型腺病毒污染的病毒载体及构建方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5976552A (en) * | 1995-04-28 | 1999-11-02 | Protein Sciences Corporation | Virus vaccines |
| AU6261696A (en) * | 1995-06-05 | 1996-12-24 | Trustees Of The University Of Pennsylvania, The | A replication-defective adenovirus human type 5 recombinant as a vaccine carrier |
| US5922576A (en) * | 1998-02-27 | 1999-07-13 | The John Hopkins University | Simplified system for generating recombinant adenoviruses |
| US6913922B1 (en) * | 1999-05-18 | 2005-07-05 | Crucell Holland B.V. | Serotype of adenovirus and uses thereof |
| US6492169B1 (en) * | 1999-05-18 | 2002-12-10 | Crucell Holland, B.V. | Complementing cell lines |
| US7094398B1 (en) * | 1999-06-01 | 2006-08-22 | University Of Washington | Recombinant adenoviral vectors expressing chimeric fiber proteins for cell specific infection and genome integration |
| EP1104813A1 (en) * | 1999-12-01 | 2001-06-06 | Leids Universitair Medisch Centrum | Conditional replication of recombinant human adenovirus DNA carrying modified inverted terminal repeat sequences |
| DK1497440T3 (da) * | 2002-04-25 | 2008-12-01 | Crucell Holland Bv | Stabile adenovirale vektorer og fremgangsmåder til propagering deraf |
-
2006
- 2006-05-23 CA CA002609276A patent/CA2609276A1/en not_active Abandoned
- 2006-05-23 KR KR1020077030182A patent/KR20080052512A/ko not_active Ceased
- 2006-05-23 WO PCT/US2006/020350 patent/WO2006127956A2/en not_active Ceased
- 2006-05-23 AU AU2006249877A patent/AU2006249877A1/en not_active Abandoned
- 2006-05-23 EP EP06760400A patent/EP1899470A4/en not_active Withdrawn
- 2006-05-23 JP JP2008513739A patent/JP2008541730A/ja active Pending
- 2006-05-23 CN CNA2006800269435A patent/CN101248186A/zh active Pending
-
2007
- 2007-11-21 US US11/943,901 patent/US20090175897A1/en not_active Abandoned
- 2007-12-13 ZA ZA200710860A patent/ZA200710860B/xx unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008541730A5 (https=) | ||
| KR101253363B1 (ko) | 개선된 아데노바이러스 벡터 및 그것의 용도 | |
| EP1649028B1 (en) | Adenoviral vector-based vaccines | |
| US12054737B2 (en) | Potent and short promoter for expression of heterologous genes | |
| CA2477954C (en) | Means and methods for the production of adenovirus vectors | |
| Barouch et al. | Adenovirus vector-based vaccines for human immunodeficiency virus type 1 | |
| CN111108192B (zh) | 非人类人猿腺病毒核酸序列和氨基酸序列、含有其的载体及其用途 | |
| US9586998B2 (en) | Methods of propagating monkey adenoviral vectors | |
| US20040002060A1 (en) | Fiber shaft modifications for efficient targeting | |
| JP6683847B2 (ja) | 強力でバランスのとれた双方向性プロモーター | |
| NO321309B1 (no) | Defektive, rekombinante adenovirus, cellelinje, samt et farmasoytisk preparat. | |
| WO2012083297A2 (en) | Adenoviral vectors with modified hexon regions | |
| EP2654786B1 (en) | Adenoviral vector-based dengue fever vaccine | |
| CN101072879B (zh) | 改良的腺病毒载体及其应用 | |
| CA2519680A1 (en) | Adenovirus particles with enhanced infectivity of dendritic cells and particles with decreased infectivity of hepatocytes | |
| Kim et al. | Development of a packaging cell line for propagation of replication-deficient adenovirus vector | |
| JP7046835B2 (ja) | 強力でバランスのとれた双方向性プロモーター | |
| JP2010119306A (ja) | アデノウイルスベクターの作製方法 | |
| HK1068371B (en) | Means and methods for the production of adenovirus vectors |